decisionhealth Newsletters, Part B News - 2018 Issue 10 (October)
Use new Q code for Zilretta injection but watch for payer limitations
Subscribe or sign in to view the full article.
Article Overview
This premium article covers a temporary HCPCS Level II coding update associated with Zilretta injections and discusses payer-related billing considerations that may affect claims processing and coverage review. It is useful for medical coders, billers, and revenue cycle staff who work with Part B drug billing, orthopedic practices, and payer authorization policies. The article also references CMS guidance and examples of insurer-specific limitations and pre-authorization requirements.
Why This Topic Matters
Billing for injectable medications can be affected by temporary code changes, Medicare payment limits, and payer-specific coverage policies. Understanding these updates helps practices reduce denials and verify whether prior authorization or other coverage restrictions apply.
What You Will Learn
- How a temporary HCPCS billing update is connected to Zilretta injections
- Why payer coverage policies can affect reimbursement and authorization workflows
- What kinds of Medicare and commercial payer considerations may be relevant to Part B drug billing
- How to identify when additional payer verification may be needed for injectable therapies
Who Should Read This
- Medical coders
- Medical billers
- Revenue cycle staff
- Orthopedic practice staff
- Practice administrators
- Compliance staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com